Ming A Li

US Patent:

6785846, Aug 31, 2004

Filed:

Dec 22, 2000

Appl. No.:

09/742372

Inventors:

Ming Y. Li - Mahwah NJ

Assignee:

Intel Corporation - Santa Clara CA

International Classification:

G06F 1100

US Classification:

714 30, 714 36, 714733

Abstract:

A system and method is provided for detecting defects in an embedded architecture or micro-processor based system. A look-up table, located with in a programmable logic device, is accessed to obtain a value for a particular byte of a predetermined data pattern. The predetermined data pattern is associated with data from a bus coupled to the programmable logic device. The accessed value of the predetermined data pattern is compared to data that is received by the programmable logic device from a memory coupled to the programmable logic device via the bus. An alarm mechanism, to indicate an improper data comparison, is triggered based upon the comparison of the predetermined data pattern and the data received from the memory.

US Patent:

8122042, Feb 21, 2012

Filed:

Jun 26, 2009

Appl. No.:

12/493105

Inventors:

Yufei Pan - North Brunswick NJ, US
Jiankuan Ye - Edison NJ, US
Ming Li - San Jose CA, US
Alessio Signorini - Boulder CO, US
Apostolos Gerasoulis - Edison NJ, US
Tomasz Imielinski - Princeton NJ, US

Assignee:

IAC Search & Media, Inc. - Oakland CA

International Classification:

G06F 17/00

US Classification:

707759, 707769

Abstract:

In a method for a direct answer for search, a search query is received over a network, one or more answer entities are determined from one or more answer candidate snippets, with an answer candidate snippet having at least a portion of content available over the network for an answer candidate, a content identifier is determined for an answer candidate, a title is tokenized for the content identifier, a comparison is performed between a vector of tokens for the title and a vector of the one or more answer entities, an indicator of the relevance is adjusted for the content identifier in accordance with the comparison, and at least one answer candidate snippet is sent for a response to the search query.

US Patent:

8588810, Nov 19, 2013

Filed:

Nov 30, 2011

Appl. No.:

13/307754

Inventors:

Jing Dai - White Plains NY, US
Ming Li - Elmsford NY, US
Milind R. Naphade - Fishkill NY, US
Sambit Sahu - Hopewell Junction NY, US

Assignee:

International Business Machines Corporation - Armonk NY

International Classification:

H04W 24/00

US Classification:

4554561, 455 412, 4554042, 4554562, 4554563, 4554566

Abstract:

A GPS-enabled cellular electronic device is operated in an indoor mode. An increase in strength of a cellular signal is detected at the GPS-enabled cellular electronic device. Responsive at least to the increase in cellular signal strength, the GPS-enabled cellular electronic device is transitioned to an outdoor testing mode. Detecting is carried out to determine whether movement of the GPS-enabled cellular electronic device occurs during the outdoor testing mode. If so, the GPS-enabled cellular electronic device is transitioned to an outdoor mode.

US Patent:

20080011693, Jan 17, 2008

Filed:

Jul 12, 2006

Appl. No.:

11/486340

Inventors:

Ming Li - Plainsboro NJ, US
ShaoXiang Lu - Plainsboro NJ, US

International Classification:

B01D 17/00

US Classification:

210802, 210521, 210540, 210DIG005

Abstract:

A self-cleaning waste-water treatment device and method having a housing; a waste-water inlet; a coalescing plate interceptor removably mounted within the housing comprising a plurality of corrugated separator plates each having apertures therein, for receiving the waste-water and for separating, via specific gravity, hydrocarbon-based contaminants from the waste-water; at least one ultrasonic generator disposed within the housing; contaminant removal means for removing separated hydrocarbon-based contaminants from the housing; a purified water outlet; and at least one baffle located adjacent to the purified water outlet.

US Patent:

20100227795, Sep 9, 2010

Filed:

Mar 3, 2009

Appl. No.:

12/397219

Inventors:

Solomon S. Steiner - Mount Kisco NY, US
Ming Li - Yorktown Heights NY, US
Robert Hauser - Columbia MD, US

International Classification:

A61K 38/28
A61P 3/10

US Classification:

514 3

Abstract:

Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration. In another embodiment, the insulin is stored as a frozen mixture, ready for use upon thawing.

US Patent:

20110097386, Apr 28, 2011

Filed:

Mar 1, 2010

Appl. No.:

12/715203

Inventors:

Solomon S. Steiner - Mount Kisco NY, US
Robert Hauser - Columbia MD, US
Ming Li - Yorktown Heights NY, US
Robert Feldstein - Yonkers NY, US

International Classification:

A61K 38/26
A61K 9/127
A61P 3/08

US Classification:

424450, 514 117

Abstract:

A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37 C.

US Patent:

20110237510, Sep 29, 2011

Filed:

Sep 27, 2010

Appl. No.:

12/891240

Inventors:

Solomon S. Steiner - Mount Kisco NY, US
Robert Hauser - Columbia MD, US
Ming Li - Yorktown Heights NY, US
Robert Feldstein - Yonkers NY, US

International Classification:

A61K 38/26
A61P 3/08
B65D 85/00

US Classification:

514 117, 2065241

Abstract:

A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37 C.

US Patent:

20120178675, Jul 12, 2012

Filed:

Jul 5, 2011

Appl. No.:

13/176435

Inventors:

Solomon Steiner - Mount Kisco NY, US
Robert Hauser - Columbia MD, US
Richard Seibert - Carmel NY, US
Ming Li - Yorktown Heights NY, US

International Classification:

A61K 38/28
A61P 25/00
A61P 3/10

US Classification:

514 64

Abstract:

Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of rapid acting injectable insulin formulations are described herein. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”) and a dissolution/stabilization agent, and optionally additional excipients. Calcium disodium EDTA is less likely to remove calcium from the body, and typically has less pain on injection in the subcutaneous tissue. Modulating the type and quantity of EDTA can change the insulin absorption profile. Increasing the quantity of citrate can further enhance absorption and chemically stabilize the formulation. In the preferred embodiment, the formulation contains human insulin, calcium disodium EDTA and a dissolution/stabilization agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection.

Address:

7816 147 St, Flushing, NY 11367

Phone:

7183805640

VIN:

4S4BRDLCXB2363873

Make:

SUBARU

Model:

OUTBACK

Year:

2011